References
- Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. J Am Med Assoc 1997; 278: 479–484
- Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001; 345: 494–502
- Berger PB, Bell MR, Rihal CS, Ting H, Barsness G, Garratt K, Bellot V, Mathew V, Melby S, Hammes L, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999; 34: 1891–1894
- Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156–4165
- Kunapuli SP. Functional characterization of platelet ADP receptors. Platelets 1998; 9: 343–351
- Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202–207
- Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222–232
- Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925–934
- Christensen K, Larsson R, Emanuelsson H, Elgue G, Larsson A. Coagulation and complement activation. Biomaterials 2001; 22: 349–355
- Christensen K, Larsson R, Emanuelsson H, Elgue G, Larsson A. Improved blood compatibility of a stent graft by combining heparin coating and abciximab. Thromb Res 2005; 115: 245–253
- Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: Dependence on the lesion substrate. Thromb Haemost 1995; 74: 552–559
- Hamon M, Bauters C, McFadden EP, Wernert N, Lablanche JM, Dupuis B, Bertrand ME. Restenosis after coronary angioplasty. Eur Heart J 1995; 16(Suppl I)33–48
- Van Belle E, Tio FO, Chen D, Maillard L, Kearney M, Isner JM. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol 1997; 29: 1371–1379
- Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528–535
- Kennedy SH, Rouda S, Qin H, Aho S, Selber J, Tan EM. Basic FGF regulates interstitial collagenase gene expression in human smooth muscle cells. J Cell Biochem 1997; 65: 32–41
- Hardhammar PA, van Beusekom HM, Emanuelsson HU, Hofma SH, Albertsson PA, Verdouw PD, Boersma E, Serruys PW, van der Giessen WJ. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996; 93: 423–430
- Serruys PW, Emanuelsson H, van der Giessen W, Lunn AC, Kiemeney F, Macaya C, Rutsch W, Heyndrickx G, Suryapranata H, Legrand V, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 1996; 93: 412–422
- Wohrle J, Al-Khayer E, Grotzinger U, Schindler C, Kochs M, Hombach V, Hoher M. Comparison of the heparin-coated vs the uncoated Jostent – no influence on restenosis or clinical outcome. Eur Heart J 2001; 22: 1808–1816
- Ekdahl KN, Elgue G, Nilsson B. Phosphorylation of coagulation factor XI by a casein kinase released by activated human platelets increases its susceptibility to activation by factor XIIa and thrombin. Thromb Haemost 1999; 82: 1283–1288
- Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 1999; 19: 170–177